Printer Friendly

INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES INTRODUCTION OF 10-MINUTE SUDS(R) HIV-1+2 ANTIBODY TEST TO INTERNATIONAL MARKETS

 NORCROSS, Ga., April 22 /PRNewswire/ -- International Murex Technologies Corporation (AMEX: MXX; TSE) (IMTC) today announced that it has begun manufacturing its Single Use Diagnostic System (SUDS/R/) HIV-1+2 Antibody Test and has commenced marketing the product into Belgium, Denmark, Holland, Norway, Portugal, Singapore, South Africa, Spain, Sweden, Thailand and the United Kingdom.
 This test is expected to be sold into the rest of the world including Africa, Europe and Southeast Asia within the next year.
 The SUDS HIV-1+2 Antibody Test simultaneously detects antibodies to HIV-1 and HIV-2, both types of the virus believed to cause AIDS. It is a screening test which requires no special equipment and only minimal user training. The test will be marketed by IMTC's internal marketing and sales staff of more than 200, as well as international distributors, that call on blood banks, clinical laboratories and hospitals. In addition, the SUDS HIV-1+2 Antibody Test will be marketed by medical distributors who currently sell Murex Diagnostics' range of over 600 immunodiagnostic products.
 The World Health Organization estimates that there are currently a total of eight to 10 million persons worldwide infected with HIV. "In some areas, outside of North America there is an increasing demand for HIV-1+2 tests because HIV-2 has spread more rapidly in these regions," stated Dr. Robert K. Shockley, Ph.D. and director, Research and Development at IMTC subsidiary, Murex Corporation.
 In clinical trials the SUDS HIV-1+2 Antibody Test sensitivity (lack of false negatives) was estimated from results of testing specimens obtained from individuals with risk factors and with a clinical diagnosis of AIDS. The sensitivity in testing 534 HIV-1 positive specimens and 169 HIV-2 positive specimens for HIV-1 and HIV-2 was 100 percent. The specificity (lack of false positives) of SUDS HIV-1+2 Antibody Test was 99.7 percent when testing 612 negative specimens from individuals without known risk factors. These figures are comparable or superior to those for other currently approved HIV-1, HIV-2 and HIV-1+2 tests used in clinical laboratories.
 "The introduction of the SUDS HIV-1+2 Antibody Test opens global markets for our rapid screening method for HIV. When we introduced the SUDS HIV-1 Antibody Test last May, we received strong interest from distributors and medical authorities in foreign countries that required an HIV-1 plus HIV-2 product. This new test, which is very accurate, meets that demand and we believe will result in an increased market share for this product line over the next year," stated C. Robert Cusick, president and chief executive officer of IMTC. IMTC achieved sales revenues of more than $1 million from the SUDS HIV-1 Antibody Test in the first nine months since introduction.
 IMTC is a medical diagnostic products company dedicated to the research, manufacture and marketing of products for the detection, monitoring and screening of infectious diseases and other medical conditions, and for blood grouping. IMTC has FDA approved manufacturing facilities in Norcross and Dartmouth, Nova Scotia. Additionally, the company's European subsidiary, Murex Diagnostics (formerly Wellcome Diagnostics) of Dartford, England, was one of the first U.K.-based in-vitro diagnostic companies certified under the ISO 9001 regulations covering the design, manufacture and distribution of medical diagnostic products. IMTC employs 670 people worldwide. The company manufactures and markets more than 650 products including a range of mass screening diagnostic tests and its unique rapid (10 minute) SUDS tests for the detection of antibodies to HIV-1 and HIV-1+2.
 For further information contact C. Robert Cusick, president and chief executive officer or Marcia M. Young, director of corporate communications at 800-322-1332 or 404-662-0660.
 -0- 4/22/93
 /CONTACT: Marcia M. Young, director of corporate communications of International Murex, 800-322-1332/
 (MXX)


CO: International Murex Technologies Corporation ST: Georgia IN: MTC SU: PDT

RA-BR -- AT013 -- 9521 04/22/93 13:37 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1993
Words:629
Previous Article:RON RHODY TO LEAVE BANK OF AMERICA
Next Article:SCANA CORPORATION ANNOUNCES INCREASE IN FIRST QUARTER EARNINGS
Topics:


Related Articles
FDA-APPROVED 10-MINUTE HIV TEST AVAILABLE IN MICHIGAN
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION SIGNS DEVELOPMENT AND LICENSE AGREEMENT FOR DNA PROBE TECHNOLOGY
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION REPORTS FIRST QUARTER 1993 FINANCIAL RESULTS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION BOARD APPOINTS DAVID THOLEN NEW PRESIDENT AND CHIEF OPERATING OFFICER
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION REPORTS SECOND QUARTER 1993 FINANCIAL RESULTS
INTERNATIONAL MUREX TECHNOLOGIES REPORTS THIRD QUARTER 1994 RESULTS STEADY GROWTH IN REVENUES, EPS AND PROFITS
INTERNATIONAL MUREX SIGNS EXCLUSIVE LICENSE WITH BIOSTAR TO MARKET SUPERIOR STREP TESTS TO A $35 MILLION MARKET
Chiron, Ortho Diagnostic Systems and International Murex Reach Worldwide HCV Agreement
International Murex Reports 1996 Year End Earnings of $0.11 Per Share
Revolutionary HIV Drug Resistance Test Launched Worldwide By International Murex

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters